Real‐world outcomes of nivolumab‐ AVD and brentuximab vedotin‐ AVD in paediatric and adult advanced‐stage Hodgkin lymphoma
Year: 2026
Type: article
Study design: Observational Study
Abstract: Brentuximab vedotin (BV)-doxorubicin, vinblastine and dacarbazine (AVD) and nivolumab (N)-AVD have transformed the frontline treatment of advanced-stage Hodgkin lymphoma (HL), yet real-world comparative data remain limited. In this multicentre retrospective study across 17 US centres, 646 patients treated between September 2011 and April 2025 were included; 509 (78.8%) received BV-AVD and 137 (21.2%) received N-AVD. Dose reductions or omissions were more common with BV-AVD (35.8% vs. 14.4%, p < 0.0001). N-AVD was associated with higher rates of neutropenia (any grade 77.2% vs. 43.9%, p < 0.0001; grade ≥3 58.1% vs. 34.0%, p < 0.0001) and infections (31.9% vs. 19.7%, p = 0.004), while grade ≥3 infections and febrile neutropenia were comparable. Neuropathy was significantly more frequent with BV-AVD (57.2% vs. 20.6%, p < 0.0001). End-of-therapy complete response rates were numerically higher with N-AVD (86.2% vs. 79.3%, p = 0.11). With a median follow-up of 26.8 months, 2-year overall survival (OS) was 97% for BV-AVD and 100% for N-AVD (p = 0.08) and 2-year progression-free survival (PFS) was 84% vs. 88% (p = 0.06). Survival outcomes were consistent in a 1:1 propensity score-matched cohort. These real-world data demonstrate comparable survival between regimens, with numerically improved PFS supporting N-AVD as a frontline standard for advanced-stage HL; however, higher rates of neutropenia and infections warrant careful monitoring and consideration of growth factor prophylaxis.
Source: British Journal of Haematology
DOI: 10.1111/bjh.70854
Authors: Karan L. Chohan, Lei Feng, Hunter Cochran, Maya Rosenberg, Leidy Isenalumhe, Elif Yilmaz, Seo‐Hyun Kim, Yun Kyoung Tiger, Pallawi Torka, Hayley Flanagan, Sharon Castellino, Jonathan D. Bender, Radhamani Kannaiyan, Justin Kahla, B. Paige DePriest, Hiba Narvel, Mallorie B. Heneghan, Samanta Catueno, Katherine Tobon, Julia Fadul, Patricia Faulkenberry, Amy Ayers, Sunita Nathan, Salmaan Mubeen, Efrat Luttwak, Jamie Flerlage, Robin E. Norris, Supreet Kaur, Olivia Tran, Chalothorn Wannaphut, Ashleigh Hawk, Miriam B. Garcia, Branko Cuglievan, Peter Riedell, Kris M. Mahadeo, Mehdi Hamadani, Catherine Diefenbach, Nancy Bartlett, Sairah Ahmed
Institutions: The University of Texas MD Anderson Cancer Center, Washington University in St. Louis, NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, New York University, Moffitt Cancer Center, Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Rush University Medical Center, Rutgers Cancer Institute, Memorial Sloan Kettering Cancer Center, University of Rochester Medicine, Children's Healthcare of Atlanta, Cincinnati Children's Hospital Medical Center, The University of Texas at San Antonio Health Science Center, University of Chicago, Duke University, Medical College of Wisconsin, University of Utah, Memorial Hermann
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W7214521772